parkinson's disease triple agonist glp-1 gip glucagon clinical trial Schematic illustration of monoagonists, dual agonists and cartrush-subscription Medication:Tirzepatide (GLP-1 + GIP) Unlike FDA-approved drugs, compounded

parkinson's disease triple agonist glp-1 gip glucagon clinical trial Schematic illustration of monoagonists, dual agonists and cartrush-subscription Medication:Tirzepatide (GLP-1 + GIP) Unlike FDA-approved drugs, compounded

Unlike FDA-approved drugs, compounded versions have not been proven to be safe, effective or consistently manufactured. https://www.kxan.com/news/compounded-glp-1-drugs -creating-concern-among-doctors-and-fda/?utm_medium=social&utm_source=facebook_KXAN_News

Novo Nordisk stated that the Wegovy pill will be available in January 2026

cartrush-subscription

Medication:Tirzepatide (GLP-1 + GIP)

As such, companies are developing oral drugs with the intention of entering this untapped market